PRTA Prothena Corporation plc
Distress ·
Bristol Myers Squibb will end its PRX019 license on January 28, 2027, dropping up to $617.5 million in milestones it could have owed. The 8-K cites an internal strategic review and gives no further reason.
Prothena expects $16 to $20 million in severance and related charges from the workforce reduction. Its Chief Regulatory Officer and Chief People Officer will leave effective August 1, 2025.
Prothena will cut about 63% of its workforce after ending birtamimab, and expects $16 to $20 million in charges, mostly cash. The 8-K gives no headcount, cash balance or savings figure.
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation, aiming to address neurodegenerative and rare peripheral amyloid diseases. Its pipeline includes wholly-owned and partnered programs for Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease and amyotrophic lateral sclerosis (ALS). Its active clinical programs are all partnered with large pharmaceutical companies: prasinezumab, in the Phase 3 PARAISO trial for early Parkinson's disease with Roche; coramitug, in the Phase 3 CLEOPATTRA trial for ATTR-CM with Novo Nordisk; BMS-986446, in the Phase 2 TargetTau-1 trial for early Alzheimer's disease with Bristol Myers Squibb; and PRX019, in a Phase 1 trial under a global partnership with Bristol Myers Squibb. Its proprietary CYTOPE technology is designed to target intracellular disease pathways in the brain and periphery. Prothena is also conducting preclinical work on PRX012, a wholly-owned anti-Abeta antibody for Alzheimer's disease, combined with a transferrin receptor technology.
| Product or program | What it is | Stage |
|---|---|---|
| prasinezumab | Parkinson's disease, partnered with Roche | Phase 3 |
| coramitug | ATTR cardiomyopathy, partnered with Novo Nordisk | Phase 3 |
| BMS-986446 | Early Alzheimer's disease, partnered with Bristol Myers Squibb | Phase 2 |
| PRX019 | Partnered with Bristol Myers Squibb in a global partnership | Phase 1 |
| CYTOPE technology | Targets intracellular disease pathways in the brain and periphery | |
| PRX012 | Wholly-owned anti-Abeta antibody for Alzheimer's disease | preclinical |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $134.9 million | $222.5 million |
| Net income (loss) | -$244.1 million | -$122.3 million |
| Cash from operations | -$163.6 million | -$150.1 million |
| Cash and equivalents | $307.5 million | $471.4 million |
Prothena Corporation plc trades under the ticker PRTA on NASDAQ.
Prothena Corporation plc is listed on NASDAQ. Our directory also records these other listings: GETTEX:0PT; LSE:0Y3M; LSX:A1KAVV.
The SEC Central Index Key (CIK) for Prothena Corporation plc is 1559053. Its filings are on SEC EDGAR.
51,336,974 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Prothena Corporation plc under Ireland.
Our directory classifies Prothena Corporation plc as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Prothena Corporation plc is IE00B91XRN20.
aibio.space lists Prothena Corporation plc among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as L2.
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation, aiming to address neurodegenerative and rare peripheral amyloid diseases. Its pipeline includes wholly-owned and partnered programs for Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).
prasinezumab: Parkinson's disease, partnered with Roche Stage: Phase 3.
coramitug: ATTR cardiomyopathy, partnered with Novo Nordisk Stage: Phase 3.
Prothena Corporation plc reported a net loss of $244.1 million for the fiscal year ended Dec 31, 2025, and used $163.6 million of cash in operations, per its annual report to the SEC.
$134.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
$288.2 million in cash at Jun 30, 2026, per its 10-Q.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio